New survival data from the Phase III CLEOPATRA study, revealed at the San Antonio Breast Cancer Symposium (SABCS), demonstrate that Perjeta reduces the risk of death by 34% in patients with previously untreated advanced HER2-positive breast cancer, compared with the current gold standard of care - Herceptin and chemotherapy (docetaxel) (HR= 0.66; 95% CI 0.52-0.84)...
More...
Linear Mode
